Use of NPSP558 in the Treatment of Hypoparathyroidism

PHASE3CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

December 18, 2008

Primary Completion Date

September 28, 2011

Study Completion Date

September 28, 2011

Conditions
Hypoparathyroidism
Interventions
DRUG

Placebo

Placebo for subcutaneous injection

DRUG

NPSP558

Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily

Trial Locations (31)

10032

Columbia University Medical Center, New York

10301

University Physicians Group, Staten Island

19104

Children's Hospital of Philadelphia, Philadelphia

27834

Physicians East, Greenville

32224

Mayo Clinic Jacksonville, Jacksonville

33012

Palm Springs Research Institute, Hialeah

45219

University of Cincinnati Bone Health and Osteoporosis Center, Cincinnati

46202

Indiana University School of Medicine, Indianapolis

48236

Michigan Bone and Mineral Clinic PC, Detroit

55905

Mayo Clinic Rochester, Rochester

60637

University of Chicago Medical Center, Chicago

76708

Hillcrest Family Health Center, Waco

78229

Cetero Research DGD Research Inc., San Antonio

85259

Mayo Clinic-Scottsdale, Scottsdale

90712

Advance Medical Research LLC, Lakewood

92868

Diabetes Associates, Orange

94127

University of California-San Francisco VA Medical Center, San Francisco

98664

The Vancouver Clinic, Vancouver

02114

Massachusetts General Hospital, Boston

BE-4000

Chetre Hospitalier Universitaire de Liege, Liège

T2N 4Z6

Heritage Medical Research Clinic, Calgary

B3H 2Y9

Capital District Health Authority, QEII Health Sciences Centre, Halifax

L6J 1X8

Oakville Bone Center, Oakville

DK-8000

Aarhus University Hospital, Aarhus

DK-5000

Odense University Hospital, Odense

F-75015

Hôpital Européen Georges Pompidou, Paris

Unknown

Semmelweis University Medical School, Budapest

University of Pécs, School of Medicine, Pécs

University of Szeged, Szeged

I - 50134

University Hospital of Careggi, Florence

L69 3GA

Royal Liverpool University Hospital, Liverpool

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Shire

INDUSTRY

NCT00732615 - Use of NPSP558 in the Treatment of Hypoparathyroidism | Biotech Hunter | Biotech Hunter